Clinical trials: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003661
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) blastic phase (BP) and if…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
- Trial name
- NCT01670084
- Testing
- nilotinib, rituximab, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- Mayo Clinic
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Acute Myelogenous Leukemia, Agnogenic Myeloid Metaplasia
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute…
- Conditions
- Acute Myelogenous Leukemia, Agnogenic Myeloid Metaplasia, Chronic Myelogenous Leukemia
- Trial name
- NCT00088231
- Testing
- Imatinib Mesylate (Gleevec), PTK 787 (vatalanib)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
- Trial name
- NCT01231919
- Testing
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 25 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of GTI-2040 in treating patients with relapsed, refractory, or high-risk acute leukemia, high-grade myelodysplastic syndromes, or refractory or blastic phase chronic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00459212
- Testing
- GTI-2040, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndromes
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
The goal of this study is to see if there is a benefit to giving chemotherapy and then natural killer (NK) cells. The NK cells must come from a family member who shares half of the patients HLA proteins.
- Trial name
- NCT00526292
- Testing
- natural killer cell therapy, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more…
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003960
- Testing
- busulfan, cyclophosphamide, methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Leukemia
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer.
- Trial name
- NCT01139151
- Testing
- 3 Day Thiarabine, 5 Day Thiarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with relapsed or refractory acute leukemia, myelodysplastic syndromes, blastic phase chronic myelogenous leukemia, or chronic…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00301769
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
- Trial name
- NCT03320642
- Testing
- Itacitinib, Calcineurin inhibitor
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Leukemia
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Dasatinib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving dasatinib together with vorinostat may kill more cancer cells.
- Trial name
- NCT00816283
- Testing
- dasatinib, vorinostat, cytogenetic analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Myelodysplastic Syndromes
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Chemotherapy, such as fludarabine and thiotepa, and radiation therapy may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00112567
- Testing
- fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center